DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
G•••• C•••••••••
Drug Discovery & Developmentgroup grade Boff every schedule since Sep 30, 2024sponsor unattributed
Nothing material in the last 200 days. No dated change on record yet.
Mark path, consensus per quarter end
101¢ · 101¢ · 101¢ · 101¢ · 102¢Q3 2023 to Q3 2024
Principal held
at least $30.2M
sum of BDC pieces, a lower bound
Fair value
$32.4M
102c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Oct 1, 2025
$30.2M inside 24 months
On the tape since
Dec 31, 2022
latest Sep 30, 2024
Events
4
dated, non-routine
Lender marks
each lender's own fair value over cost at Sep 30, 2024, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $30.2M | 102¢ | +1 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, M••••••• D••• O•••••• 2025, P•••• + 4.50%, F•••• rate 9.00%, 6.55% E••• Fe | $30.2M | $32.4M 102c | S+450 bp |
Capital structure as the BDCs see it
latest quarter end Sep 30, 2024
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Sep 30, 2024 | at least $30.2M | 102c | S+450 bp | Oct 1, 2025 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2024 | 1 | $30.2M | $32.4M | 102c | 0 |
| Jun 30, 2024 | 1 | $30.2M | $31.9M | 101c | 0 |
| Mar 31, 2024 | 1 | $30.2M | $31.5M | 101c | 0 |
| Dec 31, 2023 | 1 | $60.4M | $62.4M | 101c | 0 |
All 8 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2023 | 1 | $18.5M | $19.6M | 101c | 0 |
| Jun 30, 2023 | 1 | $18.5M | $19.5M | 101c | 0 |
| Mar 31, 2023 | 1 | $18.5M | $19.4M | 101c | 0 |
| Dec 31, 2022 | 1 | $18.5M | $19.2M | 100c | 0 |
What changed
- Facility left every BDC scheduleSep 30, 2024
- Maturity extended (observed)Jun 30, 2024
- Maturity extended (observed)Jun 30, 2024
- Spread changed (observed)Dec 31, 2023
- Maturity extended (observed)Mar 31, 2023
Full timeline · 6 eventsShow fewer
- Maturity extended (observed)Mar 31, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- GERONderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it